1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
697BC96FFA0F6B61985258139005E53CD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-what-it-takes-to-successfully-launch-an-oncology-product-in-theusa-marketplace-leveraging-line-extensions?opendocument
18
19opendocument
203.87.147.184
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Resource Allocation

What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace: Leveraging Line Extensions

ID: 5462


Features:

9 Info Graphics

20 Data Graphics

200+ Metrics


Pages/Slides: 41


Published: 2017


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace: Leveraging Line Extensions"

STUDY OVERVIEW

Pharmaceutical companies make significant investments in the development and launch of new oncology products. Consequently, companies often pursue a second indication for the same oncology product in order to not only expand a product's patient base but also to leverage savings on launch spending by using infrastructure and resources from the first indication launch.

But how much can a company expect to save from a first launch in an oncology portfolio to a second indication launch - and across what activities and staff? This benchmark study will help marketing and brand leaders better understand the leverage and synergy points for later launches in an oncology portfolio.

The study includes investment benchmarks across pre-launch, launch and post-launch periods for first indication oncology launches and second indication launches. It also compares staffing and activity spending across the first and second launches and examines areas where launch leaders can expect to leverage the most savings.

KEY TOPICS

  • Franchise Leverage or Synergy
  • Line Extension Data & Analysis
  • 1st to 2nd Launch Investment Leverage
  • 1st to 2nd Launch Staffing Leverage
  • 1st to 2nd Launch Tactical Comparison

SAMPLE KEY METRICS

  • Percentage of Spend Avoided by Using Existing Infrastructure from First Launch to Second Launch for 17 Activities
  • Percentage of Staffing Savings that can be Leveraged from First Launch to Second Launch for 17 Activities
  • Total Spend for Each Year from Launch -3 to Launch +3 for 1st Indication and 2nd Indication
  • First Year Launch Spend for Key Activities from Launch -3 to Launch Year
  • Second Year Launch Spend for Key Activities from Launch -3 to Launch Year
  • First Indication Staffing Across 11 Activities for Launch -1 Year and Launch Year
  • Second Indication Staffing Across 11 Activities for Launch -1 Year and Launch Year

SAMPLE KEY FINDING

    • First launches, irrespective of therapy areas, require heavy pre-launch staffing investment to educate the market and develop market entry footing, second indication launches bear greater field footprint post-launch -- often advancing to develop larger market opportunities.
    • Sixty percent of first launches failed to achieve their launch goals as projected in their original peak year forecasts causing these brands to trim peak sales forecasts.

METHODOLOGY


This analysis probes Oncology product staffing levels for 12 companies and 20 U.S. project launches. Executives at the VP level, Functional Heads, Senior Directors and Directors were among the participants who informed this study.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
EMD Serono; Tesaro; Amgen; Pfizer; OTSUKA; Nektar Therapeutics; Medivation; Astellas; Novartis; Bayer; Lilly; Regeneron


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.